<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318782</url>
  </required_header>
  <id_info>
    <org_study_id>P171007J</org_study_id>
    <secondary_id>2019-A01627-50</secondary_id>
    <secondary_id>DR-2019-329</secondary_id>
    <nct_id>NCT04318782</nct_id>
  </id_info>
  <brief_title>A Prospective Study for the Treatment of Severe Pulmonary Embolism With Pharmacodynamic Thrombectomy</brief_title>
  <acronym>RESPIRE</acronym>
  <official_title>A Prospective Study for the Treatment of Severe Pulmonary Embolism With Pharmacodynamic Thrombectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The mortality of severe pulmonary embolisms admitted to the resuscitation department for&#xD;
      circulatory failure remains in the range of 30-40% at the acute phase. Hemodynamic failure is&#xD;
      the leading cause of death. These patients frequently have a contraindication to&#xD;
      thrombolysis. Surgical pulmonary arterial desobstruction still leads to significant hospital&#xD;
      mortality and can't be implemented in all hospitals. Concerning advanced hemodynamic support&#xD;
      techniques, they can't always reduce mortality on themselves. There is therefore a need for&#xD;
      developing alternative approaches for less invasive pulmonary arterial desobstruction. Data&#xD;
      on the efficacy and safety of percutaneous methods of desobstruction are still too limited to&#xD;
      implement them in current practice.&#xD;
&#xD;
      AngioJet ™ PE is a device CE marked for intra-arterial desobstruction of pulmonary arteries.&#xD;
      It has been successfully tested in more than 25 patients with pulmonary embolism in France.&#xD;
      Before considering a request for reimbursement from the HAS it is necessary to have&#xD;
      propective data of sufficient quality. This phase 2a prospective study is proposed to&#xD;
      evaluate the efficacy and safety of the AngioJet ™ PE catheter use. The resulting data will&#xD;
      allow us to submit a Phase 3 controlled study to an upcoming PHRC-type project call.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">February 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate</measure>
    <time_frame>one month</time_frame>
    <description>Survival rate at one month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global mortality</measure>
    <time_frame>7 days</time_frame>
    <description>Global mortality at 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Global mortality at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism mortality</measure>
    <time_frame>7 days</time_frame>
    <description>Pulmonary Embolism mortality at 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Pulmonary Embolism mortality at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding rate</measure>
    <time_frame>7 days</time_frame>
    <description>Major bleeding rate at 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding rate</measure>
    <time_frame>30 days</time_frame>
    <description>Major bleeding rate at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant non-major bleeding</measure>
    <time_frame>7 days</time_frame>
    <description>Clinically significant non-major bleeding at 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant non-major bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Clinically significant non-major bleeding at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic recurrence rate</measure>
    <time_frame>7 days</time_frame>
    <description>Objectively confirmed thromboembolic recurrence rate at 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic recurrence rate</measure>
    <time_frame>30 days</time_frame>
    <description>Objectively confirmed thromboembolic recurrence rate at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative rate of patients requiring a surgical pulmonary thrombectomy</measure>
    <time_frame>7 days</time_frame>
    <description>Cumulative rate of patients requiring a surgical pulmonary thrombectomy at 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative rate of patients requiring a surgical pulmonary thrombectomy</measure>
    <time_frame>30 days</time_frame>
    <description>Cumulative rate of patients requiring a surgical pulmonary thrombectomy at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success rate</measure>
    <time_frame>7 days</time_frame>
    <description>Clinical success rate at 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success rate</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical success rate at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of AE/SAE</measure>
    <time_frame>30 days</time_frame>
    <description>Description of AE/SAE at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modification of the ratio of right/left ventricle diameter</measure>
    <time_frame>48 hours</time_frame>
    <description>Modification of the ratio of right/left ventricle diameter at 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modification of the scanographic pulmonary vascular obstruction score</measure>
    <time_frame>48 hours</time_frame>
    <description>Modification of the scanographic pulmonary vascular obstruction score at 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of coagulation / fibrinolysis markers</measure>
    <time_frame>7 days</time_frame>
    <description>Results of coagulation / fibrinolysis markers at 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of coagulation / fibrinolysis markers</measure>
    <time_frame>30 days</time_frame>
    <description>Results of coagulation / fibrinolysis markers at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the intensive care unit</measure>
    <time_frame>30 days</time_frame>
    <description>Length of stay in the intensive care unit</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Thrombectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pharmacodynamic thrombectomy</intervention_name>
    <description>Pharmacodynamic thrombectomy using AngioJet ™ PE Thrombectomy Catheter</description>
    <arm_group_label>Thrombectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pulmonary embolism objectively confirmed by thoracic angioTDM&#xD;
&#xD;
          -  Date of onset of pulmonary embolism 14 days prior to inclusion&#xD;
&#xD;
          -  State of shock&#xD;
&#xD;
          -  Presence of at least 6 mm thrombus in a main or lobar pulmonary artery&#xD;
&#xD;
          -  Contraindication (absolute or relative) or systemic fibrinolysis treatment failure&#xD;
             defined by persistence of shock, as defined above, more than 6 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known cardiac pathologies with right-left cardiac shunt&#xD;
&#xD;
          -  Target pulmonary artery 6 mm in diameter&#xD;
&#xD;
          -  Known heparin allergy or thrombocytopenia&#xD;
&#xD;
          -  Known severe hypersensitivity to iodine contrast products&#xD;
&#xD;
          -  Severe renal failure defined by creatinine clearance 30 ml/min Pregnant or lactating&#xD;
             patient&#xD;
&#xD;
          -  Patient not affiliated to social security&#xD;
&#xD;
          -  Patient with unhealed lesion due to recent mechanical intervention on the vessel to be&#xD;
             treated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DEL GIUDICE Costantino, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hopitaux de Paris (APHP)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GOUDE-ORY Karine</last_name>
    <phone>00331 44 84 17 22</phone>
    <email>karine.goude@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MANSEUR Hakima, MSc</last_name>
    <phone>00331 56 09 59 71</phone>
    <email>hakima.manseur@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AP-HP - Hôpital Européen Georges-Pompidou Paris</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanchez Olivier</last_name>
      <phone>00331 56 09 34 61</phone>
      <email>olivier.sanchez@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>DEAN Carole</last_name>
      <phone>00331 56 09 37 19</phone>
      <email>carole.dean@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary embolism</keyword>
  <keyword>pharmacodynamic thrombectomy</keyword>
  <keyword>endovascular embolectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie results in publication could be shared Individual participant data detailed in meta analysis protocol could be shared</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>One year after the last publication</ipd_time_frame>
    <ipd_access_criteria>Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team.&#xD;
Teams wishing obtain IPD must meet the sponsor and IP team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

